Aptevo Therapeutics Surges Over 46% After Hours On Breakthrough AML Treatment Results

Benzinga09-18

Aptevo Therapeutics Inc. APVO jumped 46.10% to $2.06 during after-hours trading on Wednesday following breakthrough clinical results demonstrating its drug’s potential to redefine frontline AML ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2568422615?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/18/Investing-With-Laptop-Online--Stock-Mark.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-09-18 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568422615","market":"us","top_or_hot":-1,"title":"Aptevo Therapeutics Surges Over 46% After Hours On Breakthrough AML Treatment Results","media":"Benzinga","content":"<div>\n<p>Aptevo Therapeutics Inc. APVO jumped 46.10% to $2.06 during after-hours trading on Wednesday following breakthrough clinical results demonstrating its drug’s potential to redefine frontline AML ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/09/47732288/aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Surges Over 46% After Hours On Breakthrough AML Treatment Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Surges Over 46% After Hours On Breakthrough AML Treatment Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-18 15:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/25/09/47732288/aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aptevo Therapeutics Inc. APVO jumped 46.10% to $2.06 during after-hours trading on Wednesday following breakthrough clinical results demonstrating its drug’s potential to redefine frontline AML ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/09/47732288/aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APVO","symbol_name":"Aptevo Therapeutics Inc.","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/25/09/47732288/aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results","article_id":"2568422615","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/18/Investing-With-Laptop-Online--Stock-Mark.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/25/09/47732288/aptevo-therapeutics-surges-over-46-after-hours-on-breakthrough-aml-treatment-results","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2568422615","pubTimestamp":1758182280,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"APVO shares rose 46.10% to $2.06 after promising clinical results, but the stock has dropped 98.84% over the past year.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"APVO":"Aptevo Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Aptevo Therapeutics因突破性AML治疗结果盘后股价飙升超过46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":1.5},"content_text":"Aptevo Therapeutics Inc. APVO jumped 46.10% to $2.06 during after-hours trading on Wednesday following breakthrough clinical results demonstrating its drug’s potential to redefine frontline AML treatment.\nCheck out the current price of APVO stock here.\nThe biotech company from Seattle reported that all patients in Cohort 3 of its Phase 1b/2 RAINIER trial went into complete remission. The trial is testing a treatment called mipletamig, combined with venetoclax and azacitidine, for newly diagnosed AML patients who can't handle strong chemotherapy.\nNo dose-limiting toxicities or cytokine release syndrome occurred across all RAINIER cohorts.\nSee Also: Why Is D-Wave Quantum Stock Spiking After Hours\n“Cohort 3 demonstrates the kind of progress that changes expectations for frontline AML therapy,” said CEO Marvin White.\nThe frontline AML market is a multi-billion-dollar opportunity, with current standard treatments achieving lower remission rates than those seen in the RAINIER trial. Additionally, 40% of patients in the trial reached minimal residual disease-negative status, which is a key sign of a better prognosis.\nEnrollment for Cohort 4 is ongoing at higher dose levels, with a conference presentation expected in fourth quarter.\nAPVO dropped by approximately 31.9% from its one-month peak of $2.07 to yesterday’s close of $1.41. Over the past year, it has lost 98.84%, and so far in 2025, it's down 98.36%.\nThe clinical-stage annual range is between $1.32 and $381.10. It has a market capitalization of $4.64 million and an average trading volume of 3.98 million shares.\nBenzinga's Edge Stock Rankings show that APVO stock is trending negatively across all time periods. Discover insights into other biotech companies.\nRead Next:\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nPhoto courtesy: Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2568422615","isCrawlerRequest":true}